miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 1, 2026

Trump’s 927-page disclosure is just a normal Tuesday for direct indexing and crypto wealth managers

View original at finance.yahoo.com
Trump’s 927-page disclosure is just a normal Tuesday for direct indexing and crypto wealth managers President Donald Trump's latest financial disclosure has drawn attention for its sheer scale: thousands of stock trades, over $1 billion in crypto income, golf revenue, book royalties, all crammed into a filing that ran…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Mo Al Adham analyzed Trump's roughly 3,700 trades in a single quarter and concluded the volume is nothing abnormal for someone using automated, direct-indexing investment strategies

    60% confidence

  • Eric Trump stated that his father's investments are held in accounts managed by third-party financial institutions with sole authority over investment decisions, executed through automated, model-based portfolios and direct indexing strategies

    60% confidence

  • Elizabeth Warren alleged that Trump and his family were benefiting from Trump holding a seat in the Oval Office

    60% confidence

  • Donald Trump said he does not personally get involved in his investment decisions, describing his accounts as a 'blind account' run by large institutions

    60% confidence

Data points we hold from this source

Donald Trump · quarterly trade count3700 trades
Donald Trump · disclosure page count927 pages
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Trump’s 927-page disclosure is just a normal Tuesday for direct indexing and crypto wealth managers — Source | Via News | es.VIA.NEWS